IMU-935: Phase 1 SAD/MAD Data in Healthy Human Subjects and Preclinical Update - Immunic Therapeutics

Skip to main content Skip to footer

Home
About
Pipeline
News
Publications
Investors
Career
Contact

Home
About
Pipeline
News
Publications
Investors
Career
Contact

Tuesday, December 14, 2021

Presentation IMU-935 Update 2021
Play Recording IMU-935 Update 2021

Immunic, Inc.

200 Avenue of the Americas
Suite 200
New York, NY 10036, USA

Phone: +1 332 2559811
Email: info@imux.com

Immunic AG

Lochhamer Schlag 21
82166 Gräfelfing
Germany

Phone: +49 89 2080 477 00
Email: info@imux.com

Допомога пацієнтам з України
Help for patients from Ukraine

About
Pipeline

Vidofludimus Calcium
IMU-856
IMU-381

News
Publications
Investors

Career
Contact
Legal Notice / Impressum

Accessibility Statement
Privacy Policy / Datenschutz

Change Privacy Settings

© 2023, Immunic Therapeutics

All rights reserved.

Home
About
Pipeline
News
Publications
Investors
Career
Contact

Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values

Vidofludimus Calcium
IMU-856
IMU-381

IR Home
News Releases
Events and Presentations
Stock Informations
Financials and SEC Filings
Corporate Governance
IR Contact

Search ...